Overview

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beth Israel Medical Center
Collaborator:
Bayer
Treatments:
Androgens
Bicalutamide
Leuprolide
Niacinamide
Sorafenib